COSTA MESA, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) today announced its plans to initiate a phase 4 study of Infergen® (Consensus Interferon), which is in development for daily use in combination with ribavirin in the treatment of hepatitis C in patients who were non-responsive to previous pegylated interferon and ribavirin therapy. The study will evaluate the use of Infergen 15 µg/day plus ribavirin (1.0-1.2 g/day) in patients who did not have an optimal response at week 12 of treatment with pegylated interferon and ribavirin.
